295 related articles for article (PubMed ID: 12805056)
1. Labile plasma iron in iron overload: redox activity and susceptibility to chelation.
Esposito BP; Breuer W; Sirankapracha P; Pootrakul P; Hershko C; Cabantchik ZI
Blood; 2003 Oct; 102(7):2670-7. PubMed ID: 12805056
[TBL] [Abstract][Full Text] [Related]
2. LPI-labile plasma iron in iron overload.
Cabantchik ZI; Breuer W; Zanninelli G; Cianciulli P
Best Pract Res Clin Haematol; 2005 Jun; 18(2):277-87. PubMed ID: 15737890
[TBL] [Abstract][Full Text] [Related]
3. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.
Pootrakul P; Breuer W; Sametband M; Sirankapracha P; Hershko C; Cabantchik ZI
Blood; 2004 Sep; 104(5):1504-10. PubMed ID: 15155464
[TBL] [Abstract][Full Text] [Related]
4. Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.
Breuer W; Ghoti H; Shattat A; Goldfarb A; Koren A; Levin C; Rachmilewitz E; Cabantchik ZI
Am J Hematol; 2012 Jan; 87(1):55-61. PubMed ID: 22125177
[TBL] [Abstract][Full Text] [Related]
5. Redox active plasma iron in C282Y/C282Y hemochromatosis.
Le Lan C; Loréal O; Cohen T; Ropert M; Glickstein H; Lainé F; Pouchard M; Deugnier Y; Le Treut A; Breuer W; Cabantchik ZI; Brissot P
Blood; 2005 Jun; 105(11):4527-31. PubMed ID: 15671444
[TBL] [Abstract][Full Text] [Related]
6. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
Blood; 2001 Feb; 97(3):792-8. PubMed ID: 11157499
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Evans P; Kayyali R; Hider RC; Eccleston J; Porter JB
Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
[TBL] [Abstract][Full Text] [Related]
8. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
9. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
Srichairatanakool S; Thephinlap C; Phisalaphong C; Porter JB; Fucharoen S
Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073
[TBL] [Abstract][Full Text] [Related]
10. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients.
Espósito BP; Breuer W; Slotki I; Cabantchik ZI
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():42-9. PubMed ID: 11886431
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice.
Thephinlap C; Phisalaphong C; Fucharoen S; Porter JB; Srichairatanakool S
Med Chem; 2009 Sep; 5(5):474-82. PubMed ID: 19534681
[TBL] [Abstract][Full Text] [Related]
12. Labile plasma iron as an indicator of patient adherence to iron chelation treatment.
Steinberg-Shemer O; Yacobovich J; Cohen M; Cabantchik IZ; Tamary H
Blood Cells Mol Dis; 2018 Jul; 71():1-4. PubMed ID: 29395830
[TBL] [Abstract][Full Text] [Related]
13. Can iron chelators influence the progression of atherosclerosis?
Marx JJ; Kartikasari AE; Georgiou NA
Hemoglobin; 2008; 32(1-2):123-34. PubMed ID: 18274990
[TBL] [Abstract][Full Text] [Related]
14. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats.
Brissot P; Bolder U; Schteingart CD; Arnaud J; Hofmann AF
Hepatology; 1997 Jun; 25(6):1457-61. PubMed ID: 9185768
[TBL] [Abstract][Full Text] [Related]
15. Consumption of a green tea extract-curcumin drink decreases blood urea nitrogen and redox iron in β-thalassemia patients.
Koonyosying P; Tantiworawit A; Hantrakool S; Utama-Ang N; Cresswell M; Fucharoen S; Porter JB; Srichairatanakool S
Food Funct; 2020 Jan; 11(1):932-943. PubMed ID: 31950948
[TBL] [Abstract][Full Text] [Related]
16. Green tea extract modulates oxidative tissue injury in beta-thalassemic mice by chelation of redox iron and inhibition of lipid peroxidation.
Koonyosying P; Kongkarnka S; Uthaipibull C; Svasti S; Fucharoen S; Srichairatanakool S
Biomed Pharmacother; 2018 Dec; 108():1694-1702. PubMed ID: 30372872
[TBL] [Abstract][Full Text] [Related]
17. Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids.
Thephinlap C; Phisalaphong C; Lailerd N; Chattipakorn N; Winichagoon P; Vadolas J; Fucharoen S; Porter JB; Srichairatanakool S
Med Chem; 2011 Jan; 7(1):62-9. PubMed ID: 21235521
[TBL] [Abstract][Full Text] [Related]
18. Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation.
Naoum FA; Espósito BP; Ruiz LP; Ruiz MA; Tanaka PY; Sobreira JT; Cançado RD; de Barros JC
Acta Haematol; 2014; 131(4):222-6. PubMed ID: 24335268
[TBL] [Abstract][Full Text] [Related]
19. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
al-Refaie FN; Wickens DG; Wonke B; Kontoghiorghes GJ; Hoffbrand AV
Br J Haematol; 1992 Oct; 82(2):431-6. PubMed ID: 1419825
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stress.
Thephinlap C; Ounjaijean S; Khansuwan U; Fucharoen S; Porter JB; Srichairatanakool S
Med Chem; 2007 May; 3(3):289-96. PubMed ID: 17504202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
